Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

CRMD

+ Watchlist+ Portfolio

CorMedix Inc.

Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$4.67
52-Week Range
$4.49 – $13.02
Market Cap
$357.92M
P/E (TTM)
7.03
EPS (TTM)
0.64
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.77
PEG Ratio
4.08
Return on Equity
15.29%
Return on Assets
12.68%
Gross Margin
87.42%
Operating Margin
41.04%
Profit Margin
15.49%
Current Ratio
2.43
Debt/Equity
0.32
Total Debt
$147.46M
Free Cash Flow
$288.82M
Revenue Growth
-47.70%
Earnings Growth
—
Enterprise Value
$150.23M

Market Snapshot

About

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Headquartered in Bridgewater, New Jersey, the company's lead product is DefenCath, a novel antimicrobial catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs) in patients receiving chronic hemodialysis. CorMedix has received FDA approval for DefenCath and is working on commercialization and market penetration. The company is also exploring additional applications for its taurolidine-based platform technology.